Abiopharma

🔍 Cislini Jeff (Executive)

Company: Revolution Medicines, Inc. (RVMD)

Report Date: 2026-08-21

Detailed Transactions and Holdings:

• Acquired 29,680 shares of Common Stock at $18.56 per share (Direct)
  Date: 2026-08-21 | Code: M | equity_swap_involved: false | shares_owned_after: 86,201.00 | transaction_form_type: 4 | Footnotes: F1, F2
• Acquired 26,600 shares of Common Stock at $21.61 per share (Direct)
  Date: 2026-08-21 | Code: M | equity_swap_involved: false | shares_owned_after: 112,801.00 | transaction_form_type: 4 | Footnotes: F1, F2
• Sold 3,400 shares of Common Stock at $207.2363 per share (Direct)
  Date: 2026-08-21 | Code: S | equity_swap_involved: false | shares_owned_after: 109,401.00 | transaction_form_type: 4 | Footnotes: F1, F3, F2
• Sold 17,323 shares of Common Stock at $208.3688 per share (Direct)
  Date: 2026-08-21 | Code: S | equity_swap_involved: false | shares_owned_after: 92,078.00 | transaction_form_type: 4 | Footnotes: F1, F4
• Sold 25,817 shares of Common Stock at $209.2497 per share (Direct)
  Date: 2026-08-21 | Code: S | equity_swap_involved: false | shares_owned_after: 66,261.00 | transaction_form_type: 4 | Footnotes: F1, F5, F2
• Sold 2,540 shares of Common Stock at $210.2647 per share (Direct)
  Date: 2026-08-21 | Code: S | equity_swap_involved: false | shares_owned_after: 63,721.00 | transaction_form_type: 4 | Footnotes: F1, F6, F2
• Sold 4,500 shares of Common Stock at $211.3417 per share (Direct)
  Date: 2026-08-21 | Code: S | equity_swap_involved: false | shares_owned_after: 59,221.00 | transaction_form_type: 4 | Footnotes: F1, F7, F2
• Sold 3,314 shares of Common Stock at $212.0583 per share (Direct)
  Date: 2026-08-21 | Code: S | equity_swap_involved: false | shares_owned_after: 55,907.00 | transaction_form_type: 4 | Footnotes: F1, F8, F2
• Sold 29,680 shares of Stock Option (Right to Buy) at $18.56 per share (Derivative)
  Date: 2026-08-21 | Code: M | Expires: 2032-02-29 | Exercise: 2026-03-01 | equity_swap_involved: false | transaction_form_type: 4 | Footnotes: F1
• Sold 26,600 shares of Stock Option (Right to Buy) at $21.61 per share (Derivative)
  Date: 2026-08-21 | Code: M | Expires: 2032-08-31 | equity_swap_involved: false | shares_owned_after: 3,500.00 | transaction_form_type: 4 | Footnotes: F1, F9

Footnotes:

• F1: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on May 22, 2026.
• F2: Includes 43,514 restricted stock units.
• F3: This transaction was executed in multiple trades in prices ranging from $206.76 to $207.75, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
• F4: This transaction was executed in multiple trades in prices ranging from $207.765 to $208.75, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
• F5: This transaction was executed in multiple trades in prices ranging from $208.77 to $209.61, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
• F6: This transaction was executed in multiple trades in prices ranging from $209.77 to $210.72, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
• F7: This transaction was executed in multiple trades in prices ranging from $210.77 to $211.76, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
• F8: This transaction was executed in multiple trades in prices ranging from $211.77 to $212.74, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
• F9: One forty-eighth (1/48th) of the shares initially subject to the option will vest on each monthly anniversary measured from September 1, 2022 (the "Vesting Commencement Date"), so that 100% of the shares subject to the option will be fully vested and exercisable as of the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service through each vesting date.